Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions - Scorecard - MDSpire
Advertisement
Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions
Clinical Scorecard: Utilization of Immune Checkpoint Inhibitors Around Liver Transplantation for Hepatocellular Carcinoma: Insights on Safety, Timing, Post-Transplant Care, and Future Perspectives
At a Glance
Category
Detail
Condition
Key Mechanisms
Immune checkpoint inhibitors (ICPIs) targeting PD-1/PD-L1 and CTLA-4 pathways, with emphasis on their role in downstaging.
Target Population
Care Setting
Transplant oncology, with a focus on neoadjuvant therapy.
Key Highlights
ICPIs can achieve tumor control and downstaging prior to liver transplantation.
Acute graft rejection risk is significant, with rates of 18%-26% pre-LT and 28%-37% post-LT.
Optimal washout periods of ≥50-90 days, ideally ~3 months, are recommended to mitigate rejection risks.
Living donor LT offers scheduling advantages for precise timing of transplantation.
Emerging biomarkers may aid in risk stratification for post-transplant ICPIs.
Guideline-Based Recommendations
Diagnosis
Utilize revised Barcelona Clinic Liver Cancer (BCLC) guidelines for patient stratification.
Management
Consider extended criteria for liver transplantation, such as UCSF criteria.
Monitoring & Follow-up
Monitor graft PD-L1 expression and alpha-fetoprotein (AFP) levels pre- and post-transplant.
Risks
Be aware of increased recurrence risks in patients who undergo downstaging.
Patient & Prescribing Data
Patients with HCC exceeding transplant criteria but eligible for downstaging.
Individualized decision-making is crucial for post-transplant ICPI use.
Clinical Best Practices
Implement a structured washout period post-ICPI therapy before transplantation.
Intensify immunosuppression post-transplant to restore graft tolerance and manage immune response.
Utilize the UNOS-DS strategy for prioritizing liver transplantation candidacy.
